DEF: Pediatrix Sets 2026 Annual Meeting Agenda, Seeks Plan Approval

Pediatrix Medical Group, Inc. announced its 2026 Annual Shareholders Meeting to vote on director elections, auditor ratification, executive compensation, and a key incentive compensation plan amendment.

Summary

• The 2026 Annual Shareholders Meeting of Pediatrix Medical Group, Inc. will be held virtually on Thursday, May 7, 2026, at 10:30 a.m. (ET).
• Shareholders will vote on the election of nine directors, the ratification of PricewaterhouseCoopers LLP as the independent registered public accounting firm for 2026, an advisory vote on 2025 executive compensation, and the approval of the Pediatrix Medical Group, Inc. Second Amended and Restated 2008 Incentive Compensation Plan.
• The Board of Directors unanimously recommends a 'FOR' vote on all proposals.
• The proposed Incentive Compensation Plan amendment seeks to increase the number of shares available for issuance by 8,000,000, extend the plan's term to May 7, 2036, and make administrative changes.
• The company achieved Adjusted Income from Operations of $231,085,000 in 2025, resulting in a 200% payout for the financial component of the annual bonus program.
• Non-financial metrics for the 2025 annual bonus program were achieved at 100%, leading to an overall bonus payout of 180% of target.
• The 2023 Performance Awards achieved 123.4% of target performance shares, with a three-year average Return on Invested Capital (ROIC) of 11.34% resulting in no further adjustment.
• Mark S. Ordan was reappointed CEO in January 2025 and received a $2,000,000 one-time cash retention award and an equity transformation award of 640,000 performance share units tied to stock price hurdles.
• Don Gregory Neeb was appointed Chief Investment and Strategy Officer in August 2025 and received a $1,000,000 one-time cash retention award and an equity transformation award of 320,000 performance share units.
• Pediatrix donated $2.6 million to various charities in 2025, primarily benefiting women's and children's health.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this filing with a moderately positive sentiment. While the company demonstrated strong operational performance in 2025 and received high shareholder approval for its compensation plan, historical financial metrics like negative net income and underperforming TSR compared to the industry index temper enthusiasm. The proposed increase in the incentive compensation plan shares is a positive for talent retention but also represents potential dilution.

Positives

• Strong financial performance in 2025 with Adjusted Income from Operations of $231,085,000, exceeding the target of $181,000,000 and leading to a 200% payout for the financial component of the annual bonus program.
• Successful achievement of non-financial metrics for the 2025 annual bonus program at 100%, contributing to an overall bonus payout of 180% of target.
• The 2023 Performance Awards earned 123.4% of target, demonstrating strong performance over the three-year period.
• Shareholders overwhelmingly approved the 2024 executive compensation program with 93.1% of votes cast in favor, indicating strong investor confidence in the compensation structure.
• Strategic leadership appointments of Mark S. Ordan as CEO and Don Gregory Neeb as Chief Investment and Strategy Officer, bringing extensive experience to drive shareholder value.
• Commitment to social responsibility, including a $2.6 million donation to women's and children's health charities in 2025 and a formal sustainability program.
• Improved operational visibility, enhanced collections performance, and strengthened revenue cycle efficiency through RCM transformation efforts.
• Successful leadership and overhead restructuring initiatives in 2024 and 2025, positioning the company as a more focused and efficient organization for 2026.
• Strengthened balance sheet and improved operating structure.

Negatives

• The company continues to operate in a dynamic healthcare environment characterized by reimbursement pressures and labor market challenges.
• The 2025 target Adjusted Income from Operations of $181 million was slightly below the 2024 actual AIFO of $183.6 million, though explained by 2024 being a leap year.
• The company's Total Shareholder Return (TSR) of $87.16 in 2025 is below the initial fixed $100 investment value, indicating a decline in stock value over time.
• The company's TSR of $53.46 in 2024 and $37.90 in 2023 also indicates significant value erosion compared to the initial $100 investment.
• The company's TSR consistently underperformed the S&P 600 Health Care Index in 2023, 2024, and 2025.
• Net income was negative in 2024 ($99,069,000) and 2023 ($60,408,000), indicating periods of unprofitability.

Risks

• Operational, regulatory, commercial, technological, financial, and strategic risks.
• Risks inherent in corporate strategy, including commercial and regulatory risk.
• Risks related to information technology, including cybersecurity.
• Incentive compensation arrangements could encourage excessive risk-taking if not properly managed.
• Challenges in the overall healthcare environment, including reimbursement pressure, labor shortages, and general operating cost increases.
• Volatility and uncertainty in the healthcare services industry due to changes (actual or anticipated) in the regulatory or payor environment.
• Unpredictable effects of same-unit volume and reimbursement-related factors, including payor mix shifts from commercial to government payors, which directly impact top-line growth and profitability.
• Difficulty in forecasting payor mix shifts over shortand long-term periods, which can result in significant reductions in average reimbursement rates.
• Competition for executive talent in the healthcare sector.

Future Outlook

The company anticipates building on the momentum from operational improvements and restructuring initiatives throughout 2026, focusing on patient-centric care, strengthening hospital relationships, and being good stewards of its improved financial position and cash flow. Despite operating in a dynamic healthcare environment with reimbursement pressures and labor market challenges, the company believes its strengthened balance sheet, improved operating structure, and focused strategic priorities position it to deliver consistent performance and create long-term value.

Management Comments

• "We are committed to employing the highest quality executive team in the healthcare services industry. We expect our executives to be of the highest caliber in terms of business acumen and integrity."
• "We strive to design an executive compensation program that is aligned with our mission while delivering value to our shareholders."
• "We believe that the continued delivery of sustainable long-term value to our shareholders requires regular dialogue."
• "Our long-term strategy emphasizes continued growth through a disciplined approach in growing organically in our specialties or adjacent specialties."
• "We look forward to building on this momentum throughout 2026."

Industry Context

StockSavvy.ai notes that Pediatrix Medical Group's focus on operational stabilization, revenue cycle management transformation, and strengthening hospital relationships aligns with broader industry trends emphasizing efficiency and strategic partnerships in a challenging healthcare landscape. The continued pressure from reimbursement and labor shortages is a common theme across the healthcare delivery sector, making disciplined capital allocation and talent retention critical for sustained performance.

Comparison to Industry Standards

• Pediatrix's Total Shareholder Return (TSR) of $87.16 in 2025, $53.46 in 2024, and $37.90 in 2023 (based on an initial $100 investment) significantly underperformed the S&P 600 Health Care Index, which reported TSRs of $77.88, $78.31, and $75.74 for the same years, respectively. This indicates a substantial lag in shareholder value creation compared to the broader healthcare market.
• The company's 2025 Adjusted Income from Operations of $231.1 million, while exceeding its internal target, should be viewed in the context of the broader industry's profitability trends, which are not explicitly detailed for direct comparison in the filing.
• The 93.1% shareholder approval for the 2024 executive compensation program is a strong indicator of alignment with investor expectations, comparable to high approval rates seen in well-governed public companies.

Management Changes

Corporate Governance

Related Party Transactions

• Catherine Stevens, daughter of Mary Ann E. Moore (Executive Vice President, General Counsel, Chief Administrative Officer and Secretary), is employed as Associate General Counsel. Her 2025 base salary was $277,021 and she received a $76,039 bonus for the 2024 bonus year.

Stakeholder Impact

• Shareholders: Direct impact through voting on directors, auditor, executive compensation, and the incentive plan. Potential dilution from increased shares in the incentive plan. Value creation tied to company performance and executive compensation alignment.
• Employees/Clinicians: Impacted by executive compensation programs designed to attract and retain talent, clinical compensation model assessments, and recruiting function transformation.
• Patients: Beneficiaries of the company's mission to provide high-quality, specialized patient care and investments in research, education, quality-improvement, and safety initiatives.
• Hospital and Health System Relationships: Renewed focus on strengthening these relationships for clinical and financial performance.
• Charities: Benefited from $2.6 million in donations in 2025, primarily for women's and children's health.

Next Steps

• Shareholders to register for the virtual 2026 Annual Shareholders Meeting by May 5, 2026, 5:00 p.m. (ET).
• Shareholders to vote on the election of nine directors, ratification of PricewaterhouseCoopers LLP, advisory vote on 2025 executive compensation, and approval of the Second Amended and Restated 2008 Incentive Compensation Plan by May 7, 2026.
• The company's leadership team will continue to operate with three key strategic priorities in mind for 2026: prioritizing patient-centric care, strengthening existing hospital and health system relationships, and being good stewards of its improved financial position and cash flow.
• Future performance goals for the second and third tranches of the 2025 performance share awards will be established at the beginning of each measurement year (2026 and 2027).
• The Compensation and Talent Committee will continue to refine its approach to executive compensation as the healthcare landscape evolves.

Key Dates

Recommendation

The company demonstrates strong operational improvements and effective executive compensation alignment, as evidenced by the 2025 financial performance and high say-on-pay approval. However, historical underperformance in Total Shareholder Return compared to the S&P 600 Health Care Index and past negative net income suggest ongoing challenges. The proposed increase in the incentive plan shares, while good for talent, also presents potential dilution. Given the mixed signals of strong internal execution against a backdrop of broader market underperformance and industry headwinds, a 'hold' recommendation is appropriate, awaiting clearer signs of sustained shareholder value creation and market outperformance.

Keywords

Pediatrix Medical Group, SEC Filing, Proxy Statement, Corporate Governance, Executive Compensation, Incentive Plan, Shareholder Meeting, Healthcare Services, Adjusted EBITDA, Risk Management, Director Election, Auditor Ratification, Stock Ownership, Sustainability, Capital Allocation